source
- Dren Bio secures $350 million to advance blood-cancer therapy toward 2027 launchDren Bio, a California biotech firm, announced it has closed a financing round that raised $350 million. The funding will be directed toward developing its lead blood‑cancer drug, with the company…
- HHS issues interim policy allowing compounding of six unapproved peptides under set conditionsHHS announced an interim policy that will not take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians that compound six unapproved peptide bulk drug su…